Abstract
Background: Biological drugs represent highly effective but costly treatments for chronic immunemediated inflammatory diseases posing substantial burden on health care budgets. Introduction of biosimilars since 2013 has brought forward the potential of market competition, and as a societal benefit, the hope of increased access at a lower cost.
Objective: We aim to provide a descriptive review on economic aspects and market changes related to the introduction of biosimilar drugs.
Method: Our focus is on chronic immune-mediated inflammatory conditions in rheumatology, gastroenterology and dermatology. Based on available literature data, we discuss the determinants of access to biological treatment, summarize the available health economic evidences with special focus on cost-utility and budget impact analyses. Market penetration of biosimilars and their overall impact on biological markets are analyzed.
Results: Biosimilar markets are country specific due to differences in the regulatory and reimbursement systems. Cost-utility analyses suggest, that given the lower price of biosimilars, formerly established biological treatment sequence practices and the eligibility criteria for biological treatment deserve reconsideration. Budget impact analyses forecasted significant budget savings in various diagnoses and countries, providing opportunity for the treatment of more patients.
Conclusion: Biosimilars may contribute to better patient-access and provide savings to governments. To increase their acceptability, further clinical evidences and real world experiences are needed, as well as education of physicians and patients. The high biosimilar penetration rates in Norway, Denmark and Poland suggest that policies which support interchanging from the reference product may be important drivers of biosimilar uptake.
Keywords: Biosimilar pharmaceuticals, access, autoimmune diseases, costs, budget impact, economics.
Current Pharmaceutical Design
Title:The Economic Impact of Biosimilars on Chronic Immune-Mediated Inflammatory Diseases
Volume: 23 Issue: 44
Author(s): Marta Pentek*, Zsombor Zrubka and Laszlo Gulacsi
Affiliation:
- Department of Health Economics, Faculty of Economics, Corvinus University of Budapest, Budapest,Hungary
Keywords: Biosimilar pharmaceuticals, access, autoimmune diseases, costs, budget impact, economics.
Abstract: Background: Biological drugs represent highly effective but costly treatments for chronic immunemediated inflammatory diseases posing substantial burden on health care budgets. Introduction of biosimilars since 2013 has brought forward the potential of market competition, and as a societal benefit, the hope of increased access at a lower cost.
Objective: We aim to provide a descriptive review on economic aspects and market changes related to the introduction of biosimilar drugs.
Method: Our focus is on chronic immune-mediated inflammatory conditions in rheumatology, gastroenterology and dermatology. Based on available literature data, we discuss the determinants of access to biological treatment, summarize the available health economic evidences with special focus on cost-utility and budget impact analyses. Market penetration of biosimilars and their overall impact on biological markets are analyzed.
Results: Biosimilar markets are country specific due to differences in the regulatory and reimbursement systems. Cost-utility analyses suggest, that given the lower price of biosimilars, formerly established biological treatment sequence practices and the eligibility criteria for biological treatment deserve reconsideration. Budget impact analyses forecasted significant budget savings in various diagnoses and countries, providing opportunity for the treatment of more patients.
Conclusion: Biosimilars may contribute to better patient-access and provide savings to governments. To increase their acceptability, further clinical evidences and real world experiences are needed, as well as education of physicians and patients. The high biosimilar penetration rates in Norway, Denmark and Poland suggest that policies which support interchanging from the reference product may be important drivers of biosimilar uptake.
Export Options
About this article
Cite this article as:
Pentek Marta *, Zrubka Zsombor and Gulacsi Laszlo , The Economic Impact of Biosimilars on Chronic Immune-Mediated Inflammatory Diseases, Current Pharmaceutical Design 2017; 23 (44) . https://dx.doi.org/10.2174/1381612824666171129193708
DOI https://dx.doi.org/10.2174/1381612824666171129193708 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Drugs Used in the Treatment of Multiple Sclerosis During COVID-19
Pandemic: A Critical Viewpoint
Current Neuropharmacology Pathology of Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Therapeutic Targets for Metastatic Prostate Cancer
Current Drug Targets Industrial Applications of C-C Coupling Reactions
Current Organic Synthesis Genetic Signatures in Ischemic Stroke: Focus on Aspirin Resistance
CNS & Neurological Disorders - Drug Targets Serpin Regulation of Fibrinolytic System: Implications for Therapeutic Applications in Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Contribution of Reactive Oxygen Species to Cartilage Degradation in Rheumatic Diseases: Molecular Pathways, Diagnosis and Potential Therapeutic Strategies
Current Medicinal Chemistry Regulation of Cell Proliferation and Apoptosis by Bioactive Lipid Mediators
Recent Patents on Anti-Cancer Drug Discovery Mesenchymal Stem Cell-Mediated Immuno-Modulatory and Anti- Inflammatory Mechanisms in Immune and Allergic Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Cross-talk between Cellular Stress, Cell Cycle and Anticancer Agents: Mechanistic Aspects
Current Medicinal Chemistry - Anti-Cancer Agents Preface
Current Cancer Drug Targets Antimicrobial Peptides and Peptidomimetics - Potent Therapeutic Allies for Staphylococcal Infections
Current Pharmaceutical Design Implications of Hepatitis B Virus Genomic Variations on Treatment Outcomes
Current Pharmacogenomics and Personalized Medicine Atherosclerosis and Arterial Blood Pressure in Mice
Current Drug Targets Does Pharmacological Therapy Still Play a Role in Preventing Sudden Death in Surgically Treated Tetralogy of Fallot?
Mini-Reviews in Medicinal Chemistry Role of Topological, Electronic, Geometrical, Constitutional and Quantum Chemical Based Descriptors in QSAR: mPGES-1 as a Case Study
Current Topics in Medicinal Chemistry Is Combination Therapy of Atosiban and Nifedipine More Effective in Preterm Labor than Each Drug Alone? A Prospective Study
Current Women`s Health Reviews Fish and Apoptosis: Molecules and Pathways
Current Pharmaceutical Design Role of MicroRNA in the Diagnosis and Therapy of Hepatocellular Carcinoma: A New Frontier
MicroRNA Cardiovascular Disease and Inflammation: Novel Biomarkers of Inflammation and Endothelial Activation
Vascular Disease Prevention (Discontinued)